Please assess the completion status of the following clinical trial:

Trial Title: Macular Edema Incidence/Severity Reduction With Nevanac

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Planned cataract extraction by phacoemulsification with the implantation of a posterior chamber intraocular lens (IOL) into the lens capsule.~* History of Type 1 or Type 2 diabetes.~* History of nonproliferative diabetic retinopathy (NPDR), mild, moderate, or severe, in the study eye as defined by the International Clinical Diabetic Retinopathy Disease Severity Scale.~* Able to understand and sign an informed consent approved by an IRB/IEC.~* Central subfield macular thickness less than or equal to 320 μm in the study eye prior to cataract surgery.~* Absence of clinically significant macular edema in the study eye as detected by clinical exam.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Signs of vitreomacular traction or epiretinal membrane in the study eye as detected by the reading center or Investigator.~* Current or previous ocular disease other than diabetic retinopathy in the study eye that, in the opinion of the Investigator, would have confounded the assessments of the macula, the retina, or central vision.~* Planned multiple procedures for the study eye during the cataract/IOL implantation surgery (eg, trabeculoplasty, corneal transplant).~* Corneal transplant in study eye.~* Baseline cumulative corneal fluorescein staining score (ie, sum of scores for all 5 corneal regions) for the study eye greater than or equal to 5, or baseline corneal fluorescein staining score in any single region for the study eye greater than or equal to 3.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NEVANAC (Type: EXPERIMENTAL): One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
- Nepafenac Vehicle (Type: PLACEBO_COMPARATOR): One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).